AIM ImmunoTech Inc.: AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic ...

AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced milestones in the expected timeline for the ongoing Phase 2 clinical study ...

Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development

Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. ("Astellas"), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical develop ...